Tarlatamab-dlle
Tarlatamab-dlle is a Bispecific T-cell Engager (BiTE) immunotherapy targeting CD3 and a first-in-class, DLL3-targeting agent. DLL3 is the abbreviation for delta-like canonical Notch ligand 3, which is expressed in ~85-96% of SCLC cells and minimally expressed among normal tissues.
The drug is indicated for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.
Provider Resource
